We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $434M
1-Year Est. Return 9.09%
This Fund
S&P 500
This Quarter Est. Return
+8.84%
1 Year Est. Return
+9.09%
3 Year Est. Return
+56.86%
5 Year Est. Return
+84.63%
10 Year Est. Return
+238.52%
AUM
$806M
AUM Growth
+$39.4M
Cap. Flow
-$29.8M
Cap. Flow %
-3.69%
Top 10 Hldgs %
34.27%
Holding
91
New
6
Increased
24
Reduced
39
Closed
2

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$24.9M
2
DVN icon
Devon Energy
DVN
+$9.55M
3
ORCL icon
Oracle
ORCL
+$9.36M
4
R icon
Ryder
R
+$8.92M
5
MSFT icon
Microsoft
MSFT
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 21.04%
2 Technology 15.29%
3 Financials 14.55%
4 Energy 11.39%
5 Consumer Staples 10.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STT icon
26
State Street
STT
$49.8B
$11.4M 1.41%
154,888
-3,450
-2% -$242K
CAH icon
27
Cardinal Health
CAH
$54.1B
$10.9M 1.36%
163,690
-408,026
-71% -$24.9M
ANF icon
28
Abercrombie & Fitch
ANF
$4.57B
$10.8M 1.35%
+329,684
New +$11.4M
SEM
29
DELISTED
Select Medical
SEM
$10.8M 1.34%
1,727,912
+810,677
+88% +$3.96M
CSX icon
30
CSX Corp
CSX
$95.7B
$10.6M 1.32%
1,107,207
-23,736
-2% -$213K
DOX icon
31
Amdocs
DOX
$5.91B
$10.6M 1.31%
256,677
-2,260
-0.9% -$88.9K
COP icon
32
ConocoPhillips
COP
$140B
$10.4M 1.29%
146,802
-1,670
-1% -$120K
TPR icon
33
Tapestry
TPR
$30.3B
$9.09M 1.13%
162,018
+870
+0.5% +$47K
DD
34
DELISTED
Du Pont De Nemours E I
DD
$8.92M 1.11%
144,583
-8,403
-5% -$486K
TAP icon
35
Molson Coors Class B
TAP
$8.05B
$8.73M 1.08%
155,503
-350
-0.2% -$18.7K
HWC icon
36
Hancock Whitney
HWC
$6.16B
$8.47M 1.05%
230,861
-13,490
-6% -$455K
VIV icon
37
Telefônica Brasil
VIV
$21.2B
$8.21M 1.02%
427,336
+19,874
+5% +$404K
NWL icon
38
Newell Brands
NWL
$2.23B
$8.15M 1.01%
251,574
-3,070
-1% -$91.3K
ORCL icon
39
Oracle
ORCL
$347B
$8.12M 1.01%
212,274
-272,176
-56% -$9.36M
DVN icon
40
Devon Energy
DVN
$49.2B
$7.78M 0.97%
125,814
-155,726
-55% -$9.55M
TDC icon
41
Teradata
TDC
$2.83B
$7.19M 0.89%
+158,000
New +$7.16M
SWK icon
42
Stanley Black & Decker
SWK
$14.9B
$6.89M 0.86%
+85,430
New +$6.99M
F icon
43
Ford
F
$59.5B
$6.34M 0.79%
+410,680
New +$6.89M
PTR
44
DELISTED
PETROCHINA COMPANY LIMITED ADS (REP 100 H SHARES)
PTR
$5.92M 0.74%
53,951
+2,133
+4% +$244K
BRK.A icon
45
Berkshire Hathaway Class A
BRK.A
$1.1T
$5.51M 0.68%
31
-12
-28% -$2.08M
EXC icon
46
Exelon
EXC
$49B
$5.16M 0.64%
264,249
+2,804
+1% +$56.4K
MTB icon
47
M&T Bank
MTB
$36.5B
$5.08M 0.63%
43,631
+70
+0.2% +$7.96K
SNY icon
48
Sanofi
SNY
$109B
$4.97M 0.62%
92,768
+1,971
+2% +$102K
IBN icon
49
ICICI Bank
IBN
$108B
$4.96M 0.62%
733,475
+282,475
+63% +$1.8M
FNB icon
50
FNB Corp
FNB
$6.79B
$4.92M 0.61%
390,100
+86,600
+29% +$1.08M

Similar funds

Foyston, Gordon, & Payne's Q4 2013 Portfolio in Review

As of Q4 2013, Foyston, Gordon, & Payne held 91 positions worth $806M, up 5.1% from $766M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Foyston, Gordon, & Payne withdrew a net $29.8M in Q4 2013, closing 2 positions and reducing 39 holdings. Its most notable exit was Unilever, an estimated $3.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Technology and Financials.

Against the trend, Foyston, Gordon, & Payne opened a new position in Baxter International worth $18M.

  • Foyston, Gordon, & Payne's largest Q4 2013 buy was Baxter International: 476,710 shares worth $18M.
  • Foyston, Gordon, & Payne added most to Conagra Brands in Q4 2013, an estimated $10.6M increase.
  • Foyston, Gordon, & Payne's biggest Q4 2013 reduction was Cardinal Health, cutting an estimated $24.9M.
  • Foyston, Gordon, & Payne fully exited Unilever in Q4 2013, selling an estimated $3.57M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 34% of its $806M portfolio in Q4 2013.
  • Foyston, Gordon, & Payne opened 6 new positions and closed 2 in Q4 2013.
  • Foyston, Gordon, & Payne's portfolio value rose 5.1% quarter-over-quarter to $806M.

Based on Foyston, Gordon, & Payne's 13F filing for Q4 2013, filed 13 Feb 2014.